PMID- 36330105
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20230126
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 10
DP  - 2022
TI  - Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin 
      aspart in Chinese population with type 2 diabetes.
PG  - 1016937
LID - 10.3389/fpubh.2022.1016937 [doi]
LID - 1016937
AB  - OBJECTIVE: To evaluate the long-term cost effectiveness of insulin 
      degludec/insulin aspart (IDegAsp) vs. biphasic insulin aspart 30 (BIAsp 30) for 
      the treatment of people with type 2 diabetes mellitus (T2DM) inadequately managed 
      on basal insulin in China. METHODS: The CORE (the Center for Outcomes Research) 
      Diabetes Model, which has been published and verified, was used to simulate 
      disease progression and calculate the total direct medical costs, life years 
      (LYs) and quality-adjusted life years (QALYs) over 30 years, from the perspective 
      of Chinese healthcare system. The patient demographic information and clinical 
      data needed for the model were gathered from a phase III treat-to-target clinical 
      trial (NCT02762578) and other Chinese cohort studies. Medical costs on treating 
      diabetes were calculated based on clinical trial and local sources. The diabetes 
      management and complications costs were derived from published literature. A 
      discounting rate of 5% was applied to both health and cost outcomes. And one-way 
      and probabilistic sensitivity analyses were carried out to test the reliability 
      of the results. RESULTS: Compared with BIAsp 30, treatment with IDegAsp was 
      associated with an incremental benefit of 0.001 LYs (12.439 vs. 12.438) and 0.280 
      QALYs (9.522 vs. 9.242) over a 30-year time horizon, and increased CNY (Chinese 
      Yuan) 3,888 (390,152 vs. 386,264) for total costs. IDegAsp was cost-effective vs. 
      BIAsp 30 therapy with an incremental cost-effectiveness ratio of CNY 13,886 per 
      QALY gained. Results were robust across a range of sensitivity analyses. 
      CONCLUSION: Compared with BIAsp 30, IDegAsp was a cost-effective treatment option 
      for people with T2DM with inadequate glycemic management on basal insulin in 
      China.
CI  - Copyright (c) 2022 Luo, Zhou, Zhou and Hu.
FAU - Luo, Qiong
AU  - Luo Q
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
FAU - Zhou, Li
AU  - Zhou L
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
FAU - Zhou, Naitong
AU  - Zhou N
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
FAU - Hu, Ming
AU  - Hu M
AD  - West China School of Pharmacy, Sichuan University, Chengdu, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02762578
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221018
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 0 (Biphasic Insulins)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - D933668QVX (Insulin Aspart)
RN  - 54Q18076QB (insulin degludec)
SB  - IM
MH  - Humans
MH  - *Biphasic Insulins/therapeutic use
MH  - Cost-Benefit Analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin/analysis/therapeutic use
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin Aspart/therapeutic use
MH  - Reproducibility of Results
MH  - Clinical Trials, Phase III as Topic
PMC - PMC9623119
OTO - NOTNLM
OT  - Biphasic insulin aspart 30
OT  - China
OT  - cost-effectiveness analysis
OT  - insulin degludec/insulin aspart
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/08 06:00
PMCR- 2022/10/18
CRDT- 2022/11/04 02:27
PHST- 2022/08/11 00:00 [received]
PHST- 2022/10/03 00:00 [accepted]
PHST- 2022/11/04 02:27 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/08 06:00 [medline]
PHST- 2022/10/18 00:00 [pmc-release]
AID - 10.3389/fpubh.2022.1016937 [doi]
PST - epublish
SO  - Front Public Health. 2022 Oct 18;10:1016937. doi: 10.3389/fpubh.2022.1016937. 
      eCollection 2022.